Search results (1331)
« Back to PublicationsVCAM-1 targeted magnetic resonance imaging enables detection of brain micrometastases from different primary tumours
CHENG VWT. et al, (2018), Clinical Cancer Research
A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours
Wilson R. et al, (2018), EUROPEAN JOURNAL OF CANCER, 103, E140 - E141
A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098.
Brown NF. et al, (2018), Neuro-oncology, 20, 1634 - 1642
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Advani R. et al, (2018), N Engl J Med, 379, 1711 - 1721
Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
Middleton MR., (2018), Lancet Oncol, 19, 1424 - 1426
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
Trotman J. et al, (2018), Lancet Oncol, 19, 1530 - 1542
Single cell RNA-seq reveals profound transcriptional similarity between Barrett’s oesophagus and oesophageal submucosal glands
LU X. et al, (2018), Nature Communications
A randomised phase II feasibility study of intermittent versus continuous dosing of targeted therapy in patients with BRAFV600 mutant advanced melanoma (INTERIM).
Corrie PG. et al, (2018), Ann Oncol, 29 Suppl 8
Comparison of the measurement properties of paper and electronic version of HM-PRO, a new patient-reported outcome measure for use in patients with haematological malignancies: an equivalence study
Goswami P. et al, (2018), QUALITY OF LIFE RESEARCH, 27, S138 - S139
OVPSYCH2: A randomised study of psychological support versus standard of care following chemotherapy for ovarian cancer.
Blagden S. et al, (2018), Ann Oncol, 29 Suppl 8, viii333 - viii334
Systematic review of patient-reported outcome measures used in randomised clinical trials testing checkpoint inhibitor immunotherapy for cancer
Peters M. et al, (2018), QUALITY OF LIFE RESEARCH, 27, S117 - S118
Publisher Correction: Telomerecat: A ploidy-agnostic method for estimating telomere length from whole genome sequencing data.
Farmery JHR. et al, (2018), Scientific reports, 8, 13376 - 13376
Management of Hodgkin lymphoma in the era of brentuximab vedotin: real-world data from five European countries.
Collins GP. et al, (2018), Leuk Lymphoma, 59, 2113 - 2120
Anti-tumor activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
BLAGDEN S. et al, (2018), British Journal of Cancer
Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.
Cross NCP. et al, (2018), British journal of haematology
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W. et al, (2018), J Clin Oncol, 36, 2395 - 2404